Emerging approaches to the treatment of uveitis: patents of 2000 – 2004

Bibliography

• DUKE-ELDERS: Diseases of the uveal tract. In: System of Ophthalmology Volume IX Henry Kimpton (Ed.), London, UK (1966):39.
   Google Scholar
• NUSSENBLATT RB: National Institute of Health: Report of the National Advisory Eye Council support for visual research. US Department of Health, Education and Welfare. Washington DC. (1976).
   Google Scholar
• ROTHOVA A, SUTTORP-VAN SCHULTEN MS, FRITS TREFFERS W, KIJLSTRA A: Causes and frequency of blindness in patients with intraocular inflammatory disease. Br. J. Ophthalmol. (1996) 80:332–336.
   PubMed Web of Science ®Google Scholar
• SUTTORP-SCHULTEN MS, ROTHOVA A: The possible impact of uveitis in blindness: a literature survey. Br. J. Ophthalmol. (1996) 80(9):844–848.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB: The natural history of uveitis. Int. Ophthalmol. (1990) 14:303–308.
   PubMed Web of Science ®Google Scholar
• BOSKOVICH SA, LOWDER CY, MEISLER DM, GUTMAN FA: Systemic diseases associated with intermediate uveitis. Cleve. Clin.j Med. (1993) 60:460–465.
   PubMed Web of Science ®Google Scholar
• BODAGHI B, CASSOUX N, WECHSLER B et al.: Chronic severe uveitis: etiology and visual outcome in 927 patients from a single center. Medicine (2001) 80:263–270.
   PubMed Web of Science ®Google Scholar
• DURRANI OM, TEHRANI NN, MARR JE, MORADI P, STAVROU P, MURRAY PI: Degree, duration, and causes of visual loss in uveitis. Br. J. Ophthalmol. (2004) 88:1159–1162.
   PubMed Web of Science ®Google Scholar
• BOYD SR, YOUNG S, LIGHTMAN S:Immunopathology of the noninfectious posterior and intermediate uveitides. Surv. Ophthalmol. (2001) 46:209–233.
   PubMed Web of Science ®Google Scholar
• CALDER VI,, SHAER B, MUHAYA M et al.: Increased CD4* expression and decreased IL-10 in the anterior chamber in idiopathic uveitis. Invest. Ophthalmol. Vis. Sci. (1999) 40:2019–2024.
   Google Scholar
• NUSSENBLATT RB: Proctor Lecture. Experimental autoimmune uveitis: mechanisms of disease and clinical therapeutic indications. Invest Ophthalmol. Vis. Sci. (1991) 32:3131–3141.
   Google Scholar
• MURPHY CC, DUNCAN L, FORRESTER JV, DICK AD: Systemic CD4* T cell phenotype and activation status in intermediate uveitis. Br. J. Ophthalmol. (2004) 88:412-416. Useful study highlighting the importance of TNF-a in uveitis.
   Google Scholar
• LIGHTMAN S, CHAN CC: Immune mechanisms in choroido-retinal inflammation in man. Eye (1990) 4(2):345–353.
   Google Scholar
• CASPI RR, ROBERGE FG, MCALLISTER CG et al.: T cell lines mediating experimental autoimmune uveoretinitis (EAU) in the rat. J. Immunol (1986) 136:928–933.
   PubMed Web of Science ®Google Scholar
• ROTHOVA A, VAN VEENEDAAL WG, LINSSEN A. GLASIUS E, KIJLSTRA A, DE JONG PT: Clinical features of acute anterior uveitis. Am. J. Ophthalmol (1987) 103:137–145.
   PubMed Web of Science ®Google Scholar
• ROMAGNANI S: T-cell subsets (TH1 versus TH2). Ann. Allergy Asthma Immunol (2000) 85:9–18.
   PubMed Web of Science ®Google Scholar
• BECKER MD, ADAMUS G, DAVEY MP, ROSENBAUM JT: The role of T cells in autoimmune uveitis. Ocul Immunol Inflamm. (2000) 8:93–100.
   PubMed Web of Science ®Google Scholar
• ALBERT LJ, INMAN RD: Molecular mimicry and autoimmunity. N Engl Med. (1999) 341:2068–2074.
   PubMed Web of Science ®Google Scholar
• HAUSMANN S, WUCHERPFENNIG KW: Activation of autoreactive T cells by peptides from human pathogens. Curr. Opin. Immunol (1997) 9:831–838.
   PubMed Web of Science ®Google Scholar
• OHASHI PS: T cell selection and autoimmunity: flexibility and tuning. Curr. Opin. Immunol (19961 8:808–814.
   Google Scholar
• BIS WAS PS, BANERJEE K, ZHENG M, ROUSE BT: Counteracting corneal immunoinflammatory lesion with interleukin-1 receptor antagonist protein. Leukoc. Biol. (2004) 76:868–875.
   Google Scholar
• JIE Y, ZHANG WH, PAN ZQ, WU YY, WANG Y: Interleukin-1 receptor antagonist eye drops promoting high-risk corneal allografts survival in rats. Chin. Med. J. (2004) 117:711–716.
   Google Scholar
• ZHOU Y, LI Z, AN W, CHIOU G: [Effects of synthetic interleukin-1 blockers on uveitis in rats]. Zhonghua Van. Ke. Za Zhi. (2000) 36:62–64.
   Google Scholar
• ROSENBAUM JT, HAN YB, PARK JM, KENNEDY M, PLANCK SR: Tumor necrosis factor-a is not essential in endotoxin induced eye inflammation: studies in cytokine receptor deficient mice. Rheumatol (1998) 25:2408–2416.
   Google Scholar
• ROSENBAUM JT, BONEY RS: Activity of an interleukin 1 receptor antagonist in rabbit models of uveitis. Arch. Ophthalmol (1992) 110:547–549.
   PubMedGoogle Scholar
• GREENWOOD J, ETIENNE-MANNEVILLE S, ADAMSON P, COURAUD PO: Lymphocyte migration into the central nervous system: implication of ICAM-1 signalling at the blood-brain barrier. VascuL PharmacoL (2002) 38:315–322.
   PubMed Web of Science ®Google Scholar
• XU H, FORRESTER JV, LIVERSIDGE J, CRANE IJ: Leukocyte trafficking in experimental autoimmune uveitis: breakdown of blood-retinal barrier and upregulation of cellular adhesion molecules. Invest. Ophthalmol Vis. Sci. (2003) 44:226–234.
   PubMed Web of Science ®Google Scholar
• XU H, MANIVANNAN A. JIANG HR et al.: Recruitment of IFN-y-producing (TH1-like) cells into the inflamed retina in vivo is preferentially regulated by P-selectin glycoprotein ligand 1:P/E-selectin interactions. J. Immunol (2004) 172:3215–3224.
   Google Scholar
• BECKER MD, GARMAN K, WHITCUP SM, PLANCK SR, ROSENBAUM JT: Inhibition of leukocyte sticking and infiltration, but not rolling, by antibodies to ICAM-1 and LFA-1 in murine endotoxin-induced uveitis. Invest. Ophthalmol Vis. Sci. (2001) 42:2563–2566.
   Google Scholar
• MARTIN CM, SANTOS LM, SERRANO MCI, RAMIREZ CR, COLLANTES EE: ICAM-1 expression on the surface of T lymphocytes in patients with uveitis: a comparative study between the eye and peripheral blood. Ophthalmologica (2002) 216:203–208.
   PubMedGoogle Scholar
• KLOK AM, LUYENDIJK L, ZAAL MJ, ROTHOVA A, KIJLSTR AA: Soluble ICAM-1 serum levels in patients with intermediate uveitis. Br. J. Ophthalmol (1999) 83:847–851.
   Google Scholar
• WHITCUP SM, VISTICA BP, MAGONE MT, GEORGE RK: Elevated serum levels of soluble ICAM-1 in uveitis patients predict underlying systemic disease. Br. J. Ophthalmol (1999) 83:252–253.
   Google Scholar
• KIM EH, MOK JW, BANG DS, LEE ES, LEE SN, PARK KS: Intercellular adhesion molecule-1 polymorphisms in Korean patients with Behcet's disease. J. Korean Med. Sci. (2003) 18:415–418.
   PubMed Web of Science ®Google Scholar
• OHTA K, NAKAYAMA K, KUROKAWAT, KIKUCHI T, YOSHIMURA N: Inhibitory effects of pyrrolidine dithiocarbamate on endotoxin-induced uveitis in Lewis rats. Invest. Ophthalmol Vis. Sci. (2002) 43:744–750.
   PubMed Web of Science ®Google Scholar
• NAMAZI MR: Cetirizine and allopurinol as novel weapons against cellular autoimmune disorders. Int. Immunopharmacol (2004) 4:349–353.
   PubMed Web of Science ®Google Scholar
• CHI ZL, HAYASAKA S, ZHANG XY, HAYASAKAY, CUI HS: Effects of rolipram, a selective inhibitor of type 4 phosphodiesterase, on lipopolysaccharide-induced uveitis in rats. Invest. Ophthalmol Vis. Sci. (2004) 45:2497–2502.
   PubMed Web of Science ®Google Scholar
• ROBICSEK SA, BLANCHARD DK, DJEU JY, KRZANOWSKI JJ: Multiple high-affinity cAMP-phosphodiesterases in human T-lymphocytes. Biochem. PharmacoL (1991) 42:869–877.
   PubMedGoogle Scholar
• VAN FURTH AM, VERHARD-SEIJMONSBERGEN EM, VAN FURTH R, LANGERMANS JA: Effect of lisofylline and pentoxifylline on the bacterial-stimulated production of TNF-a,IL-10 by human leucocytes.Immunology (1997) 91:193–196.
   PubMed Web of Science ®Google Scholar
• CHEN YI,, LE VRAUX V, GIROUD JP, CHAUVELOT-MOACHON L: Anti-tumor necrosis factor properties of non-peptide drugs in acute-phase responses. Eur. Pharmacol (1994) 271:319–327.
   PubMed Web of Science ®Google Scholar
• BIAN ZM, ELNER SG, YOSHIDA A, KUNKEL SL, SU J, ELNER VM: Activation of p38, ERK1/2 and NIK pathways is required for IL-18 and TNF-a-induced chemokine expression in human retinal pigment epithelial cells. Exp. Eye Res. (2001) 73:111–121.
   Google Scholar
• FANG IM, YANG CH, LIN CP, YANG CM, CHEN MS: Expression of chemokine and receptors in Lewis rats with experimental autoimmune anterior uveitis. Exp Eye Res. (2004) 78:1043–1055.
   Google Scholar
• ADAMUS G, MACHNICKI M, MANCZAK M: Expression of CC chemokines and their receptors in the eye in autoimmune anterior uveitis associated with EAE. Investig. Ophthalmol Vis. Sci. (2001) 42(12):2894–2903.
   Google Scholar
• CRANE J, MCKILLOP-SMITH S, WALLACE C, LAMONT G, FORRESTER J: Expression of the Chemokines MIP-1, MCP-1, and RANTES in Experimental Autoimmune Uveitis. Investig Ophthalmol Vis. Sci. (2001) 42:1547–1552.
   PubMed Web of Science ®Google Scholar
• LIVERSIDGE J, DICK A, GORDON S: Nitric oxide mediates apoptosis through formation of peroxynitrite and Fas/Fas-ligand interactions in experimental autoimmune uveitis. Am. J. PathoL (2002) 160:905–916.
   Web of Science ®Google Scholar
• CHARLOTTE F, ITO S, WU G, KIMOTO T, RAO N: Highly selective inhibitor of inducible nitric oxide synthase enhances S-antigen-induced uveitis. Curr. Eye Res. (2003) 26:1–7.
   Google Scholar
• MATTESON DM, SHEN DF, CHAN CC: Inhibition of experimental melanin protein-induced uveitis (EMIU) by targeting nitric oxide via phosphatidylcholine-specific phospholipase C. J. Autoimmun. (1999) 13:197–204.
   PubMedGoogle Scholar
• KAMATA K, INAZU M, TAKEDA H, GOTO H, MATSUMIYA T, USUI M: Effect of a selective inducible nitric oxide synthase inhibitor on intraocular nitric oxide production in endotoxin-induced uveitis rabbits: in vivo intraocular microdialysis study. PharmacoL Res. (2003) 47:485–491.
   PubMed Web of Science ®Google Scholar
• GOUREAU 0, BELLOT J, THILLAYE B, COURTOIS Y, DE KOZAK Y: Increased nitric oxide production in endotoxin-induced uveitis. Reduction of uveitis by an inhibitor of nitric oxide synthase. J. Immunol (1995) 154:6518–6523.
   Google Scholar
• MANDAI M, MITTAG TW, KOGISHI J, IWAKI M, HANGAI M, YOSHIMURA N: Role of nitric oxide synthase isozymes in endotoxin-induced uveitis. Invest. Ophthalmol Vis. Sci. (1996) 37:826–832.
   PubMedGoogle Scholar
• ROSE NR, BONA C: Defining criteria for autoimmune diseases (Witebsky's postulates revisited). Immunol. Today (1993) 14:426–430.
   PubMedGoogle Scholar
• CASPI RR: Experimental autoimmune uveoretinitis - rat and mouse. In: Autoimmune Disease Models: A Guidebook. Cohen I, Miller A (Eds), Academic Press, NY, USA (1994):57–81.
   Google Scholar
• NUSSENBLATT RB, KUWABARA T, DE MONASTERIO FM, WACKER WB: S-antigen uveitis in primates. A new model for human disease. Arch. Ophthalmol (1981) 99:1090–1092.
   PubMedGoogle Scholar
• GERY I, WIGGERT B, REDMOND TM et al.: Uveoretinitis and pinealitis induced by immunization with interphotoreceptor retinoid-binding protein. Invest. Ophthalmol. Vis. Sci. (1986) 27:1296–1300.
   PubMed Web of Science ®Google Scholar
• HIROSE S, WIGGERT B, REDMOND TM et aLUveitis induced in primates by IRBP: humoral and cellular immune responses. Exp. Eye Res. (1987) 45:695–702.
   PubMed Web of Science ®Google Scholar
• WHITCUP SM, CHAN CC, LI Q, NUSSENBLATT RB: Expression of cell adhesion molecules in posterior uveitis. Arch. Ophthalmol (1992) 110:662–666.
   PubMedGoogle Scholar
• CASPI RR: Basic mechanisms in immune-mediated uveitic disease. In: Immunology ofEye Diseases. Lightman S (Ed.), Kluwer Academic Publishers, Dordrecht (1989):61–86.
   Google Scholar
• SALINAS-CARMONA MC, NUSSENBLATT RB, GERY I: Experimental autoimmune uveitis in the athymic nude rat. Eur. j Immunol (1982) 12:480–484.
   PubMed Web of Science ®Google Scholar
• MCALLISTER CG, WIGGERT B, CHADER GJ, KUWABARA T, GERY I: Uveitogenic potential of lymphocytes sensitized to interphotoreceptor retinoid-binding protein. J. Immunol (1987) 138:1416–1420.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, KUWABARA T, MCALLISTER C, NUSSENBLATT RB, GERY I: Adoptive transfer of experimental autoimmune uveoretinitis in rats. Immunopathogenic mechanisms and histologic features. Invest. Ophthalmol Sci. (1985) 26:1–9.
   PubMed Web of Science ®Google Scholar
• MO JS, MATSUKAWA A, OHKAWARA S, YOSHINAGA M: Role and regulation of IL-8 and MCP-1 in LPS-induced uveitis in rabbits. Exp. Eye. Res. (1999) 68:333–340.
   PubMed Web of Science ®Google Scholar
• VERMA MJ, MUKAIDA N, VOLLMER-CONNA U, MATSUSHIMA K, LLOYD A, WAKEFIELD D: Endotoxin-induced uveitis is partially inhibited by anti-IL-8 antibody treatment. Invest. Ophthalmol Vis. Sci. (1999) 40:2465–2470.
   PubMed Web of Science ®Google Scholar
• BRITO BE, O'ROURKE LM, PAN Y et al.: Murine endotoxin-induced uveitis, but not immune complex-induced uveitis, is dependent on the IL-8 receptor homolog. Curr. Eye. Res. (1999) 19:76–85.
   Google Scholar
• LIGHTMAN S, KOK H: Developments in the treatment of uveitis. Expert. Opin. Investig. Drugs (2002) 11:59-67. Useful review on current treatment options in uveitis.
   Google Scholar
• CARNAHAN MC, GOLDSTEIN DA: The use of immunosuppressive drugs in uveitis. Dev. Ophthalmol (1999) 31:132–159.
   Google Scholar
• GLOMSDA BA, BLAHETA RA, HAILER NP: Inhibition of monocyte/ endothelial cell interactions and monocyte adhesion molecule expression by the immunosuppressant mycophenolate mofetil. Spinal Cord. (2003) 41:610–619.
   PubMed Web of Science ®Google Scholar
• KILMARTIN DJ, FORRESTER JV, DICK AD: Rescue therapy with mycophenolate mofetil in refractory uveitis. Lancet (1998) 352:35–36.
   PubMed Web of Science ®Google Scholar
• LARKIN G, LIGHTMAN S: Mycophenolate mofetil. A useful immunosuppressive in inflammatory eye disease. Ophthalmology (1999) 106:370–374.
   Google Scholar
• SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet (1999) 353:259–266.
   PubMed Web of Science ®Google Scholar
• ROBERTSON SM, LANG LS: Leflunomide: inhibition of S-antigen induced autoimmune uveitis in Lewis rats. Agents Actions (1994) 42:167–172.
   PubMedGoogle Scholar
• BREEDVELD FC, DAYER JM: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann. Rheum. Dis. (2000) 59:841–849.
   PubMed Web of Science ®Google Scholar
• SCHIFF MH, STRAND V, OED C, LOEW-FRIEDRICH I: Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs Today (2000) 36:383–394.
   Google Scholar
• BERTELMANN E, PLEYER U: Immunomodulatory therapy in ophthalmology - is there a place for topical application? Ophthalmologica (2004) 218:359–367.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, PALESTINE AG, CHAN CC, STEVENS G, MELLOW SD, GREEN SB: Randomized, double-masked study of cyclosporine compared to prednisolone in the treatment of endogenous uveitis. Am. J. Ophthalmol (1991) 112:138–146.
   PubMed Web of Science ®Google Scholar
• PALESTINE AG, AUSTIN HA, BALOW JE et al.: Renal histopathologic alterations in patients treated with cyclosporine for uveitis. N Engl J. Med. (1986) 314:1293–1298.
   PubMed Web of Science ®Google Scholar
• MOCHIZUKI M, MASUDA K, SAKANE T et al.: A clinical trial of FK506 in refractory uveitis. Am. J. Ophthalmol (1993) 115:763–769.
   PubMed Web of Science ®Google Scholar
• MARTIN DF, DEBARGE LR, NUSSENBLATT RB, CHAN CC, ROBERGE FG: Synergistic effect of rapamycin and cyclosporin A in the treatment of experimental autoimmune uveoretinitis. J. Immunol (1995) 154:922-927. 89.
   Google Scholar
• IKEDA E, HIKITA N, ETO K, MOCHIZUKI M: Tacrolimus-rapamycin combination therapy for experimental autoimmune uveoretinitis. Jpn. OphthalmoL (1997) 41:396–402.
   Google Scholar
• VASQUEZ EM: Sirolimus: a new agent for prevention of renal allograft rejection. Am. J. Health Syst. Pharm. (2000) 57:437–448.
   PubMed Web of Science ®Google Scholar
• FURST DE, CLEMENTS PJ: Immunosuppressives. In: Rheumatology, Klippel JH, Dieppe PA (Eds), Mosby, London (1998):3.9.1–3.9.9.
   Google Scholar
• ROSENBAUM JT: Treatment of severe refractory uveitis with intravenous cyclophosphamide. J. RheumatoL (1994) 21:123–125.
   PubMed Web of Science ®Google Scholar
• OZYAZGAN Y, YURDAKUL S, YAZICI H et al.: Low dose cyclosporin A versus pulsed cyclophosphamide in Behcet's syndrome: a single masked trial. Br. J. OphthalmoL (1992) 76:241–243.
   PubMed Web of Science ®Google Scholar
• MASUDA K, NAKAJIMA A, URAYAMA A, NAKAE K, KOGURE M, INABA G: Double-masked trial of cyclosporin versus colchicine and long-term open study of cyclosporin in Behcet's disease. Lancet (1989) 1:1093–1096.
   PubMed Web of Science ®Google Scholar
• O'DUFFY JD, ROBERTSON DM, GOLDSTEIN NP: Chlorambucil in the treatment of uveitis and meningoencephalitis of Behcet's disease. Am. J. Med. (1984) 76:75–84.
   PubMed Web of Science ®Google Scholar
• ABDALLA MI, EL D: Long-lasting remission of Behcet's disease after chlorambucil therapy. Br. J. OphthalmoL (1973) 57:706–711.
   PubMed Web of Science ®Google Scholar
• TESSLER HH, JENNINGS T: High-dose short-term chlorambucil for intractable sympathetic ophthalmia and Behcet's disease. Br. J. OphthalmoL (1990) 74:353–357.
   PubMed Web of Science ®Google Scholar
• BERK PD, GOLDBERG JD, SILVERSTEIN MN et al.: Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N EngL J. Med. (1981) 304:441–447.
   PubMed Web of Science ®Google Scholar
• KOTTER I, ECKSTEIN AK, STUBIGER N, ZIERHUT M: Treatment of ocular symptoms of Behcet's disease with interferon a 2a: a pilot study. Br. J. OphthalmoL (1998) 82:488–494.
   PubMed Web of Science ®Google Scholar
• WECHSLER B, BODAGHI B, HUONG DL et al.: Efficacy of interferon a-2a in severe and refractory uveitis associated with Behcet's disease. OcuL ImmunoL Inflamm. (2000) 8:293-301. KIJLSTRA A: Cytokines: their role in uveal disease. Eye (1997) 11(2):200–205. Useful review on cytokines and uveitis.
   Google Scholar
• VASSALLI P: The pathophysiology of tumor necrosis factors. Annu. Rev. ImmunoL (1992) 10:411–452.
   PubMed Web of Science ®Google Scholar
• GREINER K, MURPHY CC, WILLERMAIN F et al.: Anti-TNF-a therapy modulates the phenotype of peripheral blood CD4* T cells in patients with posterior segment intraocular inflammation. Invest. OphthalmoL Vis. Sci. (2004) 45:170–176.
   PubMed Web of Science ®Google Scholar
• MURPHY CC, AYLIFFE WH, BOOTH A. MAKANJUOLA D, ANDREWS PA, JAYNE D: Tumor necrosis factor a blockade with infliximab for refractory uveitis and scleritis. Ophthalmology (2004) 111:352–356.
   Google Scholar
• SMITH JR, LEVINSON RD, HOLLAND GN et al.: Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arth. Rheum. (2001) 45:252–257.
   PubMed Web of Science ®Google Scholar
• •A good comparison of two different anti-TNF-a treatments. 94. The Lenercept Multiple Sclerosis Study Group, The University of British Columbia MS/MRI Analysis Group. TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology (1999) 53:457–65.
   Google Scholar
• SMITH JR, ROSENBAUM JT: Neurological concomitants of uveitis. Br. J. OphthalmoL (2004) 88:1498–1499.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, THOMPSON DJ, LI Z et al.: Humanized anti-interleukin-2 (IL-2) receptor a therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration. J. Autoimmun. (2003) 21:283–293.
   PubMed Web of Science ®Google Scholar
• DICK AD, MEYER P, JAMES T et al.: Campath-1H therapy in refractory ocular inflammatory disease. Br. J. OphthalmoL (2000) 84:107–109.
   PubMed Web of Science ®Google Scholar
• WALDMANN H: Therapeutic approaches for transplantation. Curr. Opin. ImmunoL (2001) 13(5):606–610.
   Google Scholar
• ROSENBAUM JT: Treatment of severe refractory uveitis with intravenous cyclophosphamide. j RheumatoL (1994) 21:123–125.
   PubMed Web of Science ®Google Scholar
• NUSSENBLATT RB, GERY I, WEINER HL et al.: Treatment of uveitis by oral administration of retinal antigens: results of a phase I/II randomized masked trial. Am. J. OphthalmoL (1997) 123:583–592.
   PubMed Web of Science ®Google Scholar
• THURAU SR, DIEDRICHS-MOHRING M, FRICKE H, BURCHARDI C, WILDNER G: Oral tolerance with an HLA-peptide mimicking retinal autoantigen as a treatment of autoimmune uveitis. ImmunoL Lett. (1999) 68:205–212.
   PubMed Web of Science ®Google Scholar
• ALPSOY E, KODELJA V, GOERDT S, ORFANOS CE, ZOUBOULIS CHC: Serum of patients with Behcet's disease induces classical (pro-inflammatory) activation of human macrophages in vitro. Dermatology (2003) 206:225–232.
   PubMed Web of Science ®Google Scholar
• BARDAK Y, ARIDOGAN BC: The demonstration of serum interleukin 6-8, tumor necrosis factor-a, complement, and immunoglobulin levels in Behcet's disease with ocular involvement. OcuL ImmunoL Inflamm. (2004) 12:53–58.
   PubMed Web of Science ®Google Scholar
• BEN AHMED M, HOUMAN H, MILED M, DELLAGI K, LOUZIR H: Involvement of chemokines and TH1 cytokines in the pathogenesis of mucocutaneous lesions of Behcet's disease. Arthritis Rheum. (2004) 50:2291–2295.
   PubMed Web of Science ®Google Scholar
• FREIRE ADE L, BERTOLO MB, DE PINHO AJ, SAMARA AM, FERNANDES SR: Increased serum levels of interleukin-8 in polyarteritis nodosa and Behcet's disease. Clin. RheumatoL (2004) 23:203–205.
   PubMed Web of Science ®Google Scholar
• KABURAKI T, FUJINO Y, KAWASHIMA H et al.: Plasma and whole-blood chemokine levels in patients with Behcet's disease. Graefes Arch. Clin. Exp. OphthalmoL (2003) 241:353–358.
   PubMed Web of Science ®Google Scholar
• MANTAS C, DIRESKENELI H, OZ D, YAVUZ S, AKOGLU T: IL-8 producing cells in patients with Behcet's disease. Clin. Exp. RheumatoL (2000) 18:249–251.
   PubMedGoogle Scholar
• ZOUBOULIS CC, MAY T: Pathogenesis of Adamantiades-Behcet's disease. Med. MicrobioL ImmunoL (2003) 192:149–155.
   PubMed Web of Science ®Google Scholar
• WANG P, SUN SH, SILVER PB et al.: Methimazole protects from experimental autoimmune uveitis (EAU) by inhibiting antigen presenting cell function and reducing antigen priming. J. Leukoc. Biol. (2003) 73:57–64.
   Google Scholar
• QIAN Y, DANA MR: Effect of locally administered anti-CD154 (CD40 ligand) monoclonal antibody on survival of allogeneic corneal transplants. Cornea (2002) 21:592–597.
   PubMed Web of Science ®Google Scholar
• SRINIVASAN M, LU D, ERI RD, BRAND DD, HAQUE A, BLUM JS: CD80 binding polyproline helical peptide inhibits T cell activation. J. Biol. Chem. (2004) 280(11):10 149-10 155.
   Google Scholar
• BIAN ZM, ELNER SG, YOSHIDA A, ELNER VM: Human RPE-monocyte co-culture induces chemokine gene expression through activation of MAPK and NIK cascade. Exp. Eye Res. (2003) 76:573–583.
   Google Scholar
• XU H, STRASSMANN G, CHAN CC et al.: Protective effect of the type IV phosphodiesterase inhibitor rolipram in EAU: protection is independent of IL-10-inducing activity. Invest. Ophthalmol. Vis. Sci. (1999) 40:942–950.
   PubMed Web of Science ®Google Scholar
• FITZSIMMONS WE, FIRST MR: FK778, A synthetic malononitrilamide. Yonsei Med. J. (2004) 45:1132–1135.
   Google Scholar
• SCHREPFER S, DEUSE T, SCHAFER H, REICHENSPURNER H: FK778, a novel immunosuppressive agent, reduces early adhesion molecule up-regulation and prolongs cardiac allograft survival. Transpl. Int. (2005) 18:215–220.
   Google Scholar